NOVARTIS N - Dusseldorf Stock Exchang (NOT DU) stock market data APIs
€111.0003
0.04(0%)
as of October 17, 2025
Try our APIs with
free plan!
NOVARTIS N - Dusseldorf Stock Exchang Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for NOT.DU.
Prev. Close
111.0003
Open
111.0423
High
112.3793
Low
111.0423
52 wk Range
71.5574-114.46
Market Cap
160 075 M
Dividends (Yield)
0.0487
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get NOVARTIS N - Dusseldorf Stock Exchang data using free add-ons & libraries
Get NOVARTIS N - Dusseldorf Stock Exchang Fundamental Data
NOVARTIS N - Dusseldorf Stock Exchang Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
Get NOVARTIS N - Dusseldorf Stock Exchang End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
NOVARTIS N - Dusseldorf Stock Exchang News
New
Diorasis Therapeutics Welcomes Dr. Dimitri Azar to Its Board of Directors
BOSTON, October 17, 2025--(BUSINESS WIRE)--Diorasis Therapeutics, a Boston-based biotechnology company developing durable gene therapies for glaucoma and other ophthalmic diseases, today announced the...
Novartis Says European Regulator Backs Expanded Use of Blood Cancer Drug
Novartis (NVS) said Friday that the Committee for Medicinal Products for Human Use of the European M PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population
Novartis Pharma AG After 5 years, Kisqali® plus endocrine therapy consistently shows significant and clinically meaningful benefit in invasive disease-free survival1 Kisqali remains the only CDK4/6...
Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML
Novartis Pharma AG If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, expanding access to four times as many patients...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
